Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: implications for anticancer drug screening programs

R M Phillips, J Pearce, P M Loadman, M C Bibby, Patricia A Cooper, D J Swaine, J A Double

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The National Cancer Institute uses the hollow fiber assay as part of its screening program for anticancer drug discovery. Angiogenesis to hollow fibers implanted s.c. has not been reported, thereby raising concerns about the efficiency of drug delivery and its subsequent effects on chemosensitivity. By extending postimplantation times beyond the 6-day period presently used, extensive vascular networks develop, resulting in both increased delivery and chemosensitivity to doxorubicin. This study suggests that present protocols used to evaluate compounds may produce false negative results, and additional studies to determine the predictive value of the assay are required.

Original languageEnglish
Pages (from-to)5263-5266
Number of pages4
JournalCancer Research
Volume58
Issue number23
Publication statusPublished - 1 Dec 1998
Externally publishedYes

Fingerprint Dive into the research topics of 'Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: implications for anticancer drug screening programs'. Together they form a unique fingerprint.

  • Cite this